Clinical Trial Detail

NCT ID NCT04021368
Title SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ryvu Therapeutics SA
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

SEL120-34A

Age Groups: adult senior

No variant requirements are available.